Compare KMT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMT | AGIO |
|---|---|---|
| Founded | 1938 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 1994 | 2013 |
| Metric | KMT | AGIO |
|---|---|---|
| Price | $29.72 | $33.51 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $36.00 | ★ $38.88 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | ★ 268.33 | N/A |
| EPS | ★ 4.42 | N/A |
| Revenue | ★ $2,356,698,000.00 | $43,011,000.00 |
| Revenue This Year | $14.24 | $76.75 |
| Revenue Next Year | $7.57 | $170.73 |
| P/E Ratio | $6.83 | ★ N/A |
| Revenue Growth | ★ 19.82 | N/A |
| 52 Week Low | $20.35 | $22.24 |
| 52 Week High | $43.81 | $46.00 |
| Indicator | KMT | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 47.79 |
| Support Level | $28.23 | $26.71 |
| Resistance Level | $35.50 | $36.04 |
| Average True Range (ATR) | 0.99 | 1.25 |
| MACD | -0.03 | 0.17 |
| Stochastic Oscillator | 36.20 | 36.97 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.